Should we abandon PSA testing or make it more targeted?
This is an excerpt of a story that appeared in Cancer Therapy Advisor. Read the full article here.
prostate-specific antigen (PSA) testing, leading the United States Preventive Services Task Force (USPSTF) to recommend in 2012 against PSA testing for healthy men.The landmark Prostate, Lung, Colorectal, and Ovary (PLCO) Cancer Screening Trial found no survival benefit from
The European Randomized Study for Screening of Prostate Cancer (ERSPC), however, found that PSA testing did reduce prostate-specific mortality. The efficacy of PSA testing has since been the subject of intense debate.
A recent evaluation of the PLCO trial found that it was deeply flawed, as more than 80% of men in the unscreened control arm received a PSA test at least once during the study.